Efficacy and safety of long‐acting intramuscular testosterone undecanoate in aging men: a randomised controlled study
- 12 April 2013
- journal article
- research article
- Published by Wiley in BJU International
- Vol. 111 (7) , 1130-1140
Abstract
Objective: To evaluate the efficacy and safety of long‐acting i.m. testosterone undecanoate ( TU ) in Malaysian men with testosterone deficiency ( TD ). Patients and Methods: A total of 120 men, aged 40–70 years, with TD (serum total testosterone [ TT ] ≤ 12 nmol/L) were randomised to receive either i.m. TU (1000 mg) or placebo. In all, 58 and 56 men in the placebo and treatment arm, respectively, completed the study. Participants were seen six times in the 48‐week period and the following data were collected: physical examination results, haemoglobin, haematocrit, TT , lipid profile, fasting blood glucose, sex hormone‐binding globulin, liver function test, prostate‐ specific antigen ( PSA ) and adverse events. Results: The mean ( sd ) age of the participants was 53.4 (7.6) years. A significant increase in serum TT ( P < 0.001), PSA ( P = 0.010), haematocrit ( P < 0.001), haemoglobin ( P < 0.001) and total bilirubin ( P = 0.001) were seen in the treatment arm over the 48‐week period. Two men in the placebo arm and one man in the treatment arm developed myocardial infarction. Common adverse events observed in the treatment arm included itching/swelling/pain at the site of injection, flushing and acne. Overall, TU injections were well tolerated. Conclusions: TU significantly increases serum testosterone in men with TD . PSA , haemoglobin and haematocrit were significantly elevated but were within clinically safe limits. There was no significant adverse reaction that led to the cessation of treatment.Keywords
This publication has 52 references indexed in Scilit:
- The triad of erectile dysfunction, testosterone deficiency syndrome and metabolic syndrome: findings from a multi-ethnic Asian men study (The Subang Men’s Health Study)The Aging Male, 2011
- Testosterone Replacement in Hypogonadal Men With Type 2 Diabetes and/or Metabolic Syndrome (the TIMES2 Study)Diabetes Care, 2011
- Re: Adverse Events Associated With Testosterone AdministrationEuropean Urology, 2011
- Adverse Events Associated with Testosterone AdministrationNew England Journal of Medicine, 2010
- Adverse Effects of Testosterone Therapy in Adult Men: A Systematic Review and Meta-AnalysisThe Journal of Clinical Endocrinology & Metabolism, 2010
- Testosterone Therapy in Men with Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice GuidelineThe Journal of Clinical Endocrinology & Metabolism, 2010
- Effects of Testosterone on Muscle Strength, Physical Function, Body Composition, and Quality of Life in Intermediate-Frail and Frail Elderly Men: A Randomized, Double-Blind, Placebo-Controlled StudyThe Journal of Clinical Endocrinology & Metabolism, 2010
- Lower serum testosterone is independently associated with insulin resistance in non-diabetic older men: the Health In Men StudyEuropean Journal of Endocrinology, 2009
- Investigation, treatment and monitoring of late-onset hypogonadism in malesEuropean Journal of Endocrinology, 2008
- Prevalence of hypogonadism in males aged at least 45 years: the HIM studyInternational Journal Of Clinical Practice, 2008